Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting ...

Colorectal cancer is the third most common cancer worldwide and is also the second leading cause of cancer-related deaths in ...

Younger patients with grade 3 oligodendroglioma have fewer molecular abnormalities and longer survival than older patients, a ...

Research shows specific plant foods rich in methyl adaptogens can reverse biological aging by approximately 2 years over 8 ...

Geron Corporation , a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock ...

Tocotrienols, a form of vitamin E, could help preserve telomere length, which correlates directly to cellular ageing.

MAIA Biotechnology, Inc.’s MAIA share price has surged by 11.93%, which has investors questioning if this is right time to sell.

The data helps to justify Geron's faith in telomerase as a target in cancer, a category that has been on the pharma industry's radar for decades, but has yet to deliver a molecule to market.

The first-in-class telomerase inhibitor has since been launched ... It has also been included in updated National Comprehensive Cancer Network (NCCN) treatment guidelines for MDS.

MAIA Biotechnology, Inc. ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that two of the Company's ...